Product Name: GFAP R416WT
Product Number: AB-NN260-2
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: Glial fibrillary acidic protein
Target Alias: Intermediate filament protein; Astrocyte; gfapl; DKFZp459C0729; MGC139638; FLJ45472; AI836096; GFAP
Product Type Specific: Cytoskeletal protein pan-specific antibody
Antibody Code: NN260-2
Antibody Target Type: Pan-specific
Protein UniProt: P14136
Protein SigNET: P14136
Antibody Type: Monoclonal
Antibody Host Species: Mouse
Antibody Ig Isotype Clone: IgG1
Target Alias: Intermediate filament protein; Astrocyte; gfapl; DKFZp459C0729; MGC139638; FLJ45472; AI836096; GFAP
Product Type Specific: Cytoskeletal protein pan-specific antibody
Antibody Code: NN260-2
Antibody Target Type: Pan-specific
Protein UniProt: P14136
Protein SigNET: P14136
Antibody Type: Monoclonal
Antibody Host Species: Mouse
Antibody Ig Isotype Clone: IgG1
Antibody Immunogen Source: Synthetic peptide amino acids 411-422 (KTVEMRDGEVIK) of human GFAP; 100% identical in rat and mouse. >50% identity with other proteins (Vimentin, Desmin and Peripherin).
Production Method: Protein G purified
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 50% glycerol, 0.1% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Immunohistochemistry | ICC/Immunofluorescence
Production Method: Protein G purified
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 50% glycerol, 0.1% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Immunohistochemistry | ICC/Immunofluorescence
Antibody Dilution Recommended: WB (1:1000); optimal dilutions for assays should be determined by the user.
Antibody Potency: Detects a ~50 kDa protein in cell and tissue lysates by Western blotting.
Antibody Species Reactivity: Human | Mouse | Rat
Antibody Positive Control: 1 µg/ml of SMC-442 was sufficient for detection of GFAP R416WT in 20 µg of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Antibody Cross Reactivity: Does not cross-react with GFAP-R416W or other proteins (based on KO validation results).
Antibody Potency: Detects a ~50 kDa protein in cell and tissue lysates by Western blotting.
Antibody Species Reactivity: Human | Mouse | Rat
Antibody Positive Control: 1 µg/ml of SMC-442 was sufficient for detection of GFAP R416WT in 20 µg of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Antibody Cross Reactivity: Does not cross-react with GFAP-R416W or other proteins (based on KO validation results).
Scientific Background: The 50 kDa type III intermediate filament protein glial fibrillary acidic protein (GFAP) is a major structural component of astrocytes. GFAP associates with the calcium binding protein annexin II-p2 and S-100. Association with these proteins together with phosphorylation regulates GFAP polymerization. Astroycytes respond to brain injury by proliferatin (astrogliosis), and one of the first events to occur during astrocyte proiliferation is increased GFAP expression. Interestingly, antibodies to GFAP have been detected in individuals with dementia.
References
[1] Velasco M.E. et al. (1980) Cancer. 45:484.
[2] Bonnin J.M. et al. (1984) Acta Neuropathology. 62:185.
[3] Lee VM-Y. et al. (1984) J. Neurochem. 42:25-32 (1984).
[4] Trojanowski JQ et al. (1986) J. Neurochem. 6(3): 650-660 (1986).
[5] Schmidt ML et al; Lab Invest 56:282-294 (1987).
[6] Kosik KS et al; Neuron 1:817-825 (1988).
[7] Schmidt ML et al; Lab Invest 59:460-466 (1988).
[8] Mokuna, K, et al: J Neurosci Res 23:396 (1989).
[1] Velasco M.E. et al. (1980) Cancer. 45:484.
[2] Bonnin J.M. et al. (1984) Acta Neuropathology. 62:185.
[3] Lee VM-Y. et al. (1984) J. Neurochem. 42:25-32 (1984).
[4] Trojanowski JQ et al. (1986) J. Neurochem. 6(3): 650-660 (1986).
[5] Schmidt ML et al; Lab Invest 56:282-294 (1987).
[6] Kosik KS et al; Neuron 1:817-825 (1988).
[7] Schmidt ML et al; Lab Invest 59:460-466 (1988).
[8] Mokuna, K, et al: J Neurosci Res 23:396 (1989).
[9] Molenaar, et al; Exp Neurology 108:1-9 (1990).
[10] Tohyama T et al; Am J Pathol, 142:871-882 (1993).
[11] Tohyama T et al; Am J Pathol 142:883-892 (1993).
[12] Thilenius, A.R.B., et al; J. Immunol. 162(2): 643-650 (1999).
[10] Tohyama T et al; Am J Pathol, 142:871-882 (1993).
[11] Tohyama T et al; Am J Pathol 142:883-892 (1993).
[12] Thilenius, A.R.B., et al; J. Immunol. 162(2): 643-650 (1999).
© Kinexus Bioinformatics Corporation 2017